354 related articles for article (PubMed ID: 10416607)
21. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
Kelly T; Suva LJ; Huang Y; Macleod V; Miao HQ; Walker RC; Sanderson RD
Cancer Res; 2005 Jul; 65(13):5778-84. PubMed ID: 15994953
[TBL] [Abstract][Full Text] [Related]
22. The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.
Shan S; Lockhart AC; Saito WY; Knapp AM; Laderoute KR; Dewhirst MW
Clin Cancer Res; 2001 Aug; 7(8):2590-6. PubMed ID: 11489843
[TBL] [Abstract][Full Text] [Related]
23. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis.
Goldshmidt O; Zcharia E; Abramovitch R; Metzger S; Aingorn H; Friedmann Y; Schirrmacher V; Mitrani E; Vlodavsky I
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10031-6. PubMed ID: 12097647
[TBL] [Abstract][Full Text] [Related]
24. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening.
Hammond E; Li CP; Ferro V
Anal Biochem; 2010 Jan; 396(1):112-6. PubMed ID: 19748475
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88.
Fairweather JK; Hammond E; Johnstone KD; Ferro V
Bioorg Med Chem; 2008 Jan; 16(2):699-709. PubMed ID: 17967543
[TBL] [Abstract][Full Text] [Related]
26. The impact of heparanese and heparin on cancer metastasis and angiogenesis.
Vlodavsky I; Abboud-Jarrous G; Elkin M; Naggi A; Casu B; Sasisekharan R; Ilan N
Pathophysiol Haemost Thromb; 2006; 35(1-2):116-27. PubMed ID: 16855356
[TBL] [Abstract][Full Text] [Related]
27. Colorimetric heparinase assay for alternative anti-metastatic activity.
Ahn SC; Kim BY; Oh WK; Park YM; Kim HM; Ahn JS
Life Sci; 2006 Sep; 79(17):1661-5. PubMed ID: 16806278
[TBL] [Abstract][Full Text] [Related]
28. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
29. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
30. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.
Hulett MD; Freeman C; Hamdorf BJ; Baker RT; Harris MJ; Parish CR
Nat Med; 1999 Jul; 5(7):803-9. PubMed ID: 10395326
[TBL] [Abstract][Full Text] [Related]
31. Heparanases and tumor metastasis.
Nakajima M; Irimura T; Nicolson GL
J Cell Biochem; 1988 Feb; 36(2):157-67. PubMed ID: 3281960
[TBL] [Abstract][Full Text] [Related]
32. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
Sanderson RD; Yang Y; Suva LJ; Kelly T
Matrix Biol; 2004 Oct; 23(6):341-52. PubMed ID: 15533755
[TBL] [Abstract][Full Text] [Related]
33. Tranilast inhibits the growth and metastasis of mammary carcinoma.
Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
[TBL] [Abstract][Full Text] [Related]
34. Involvement of heparanase in tumor metastasis and angiogenesis.
Vlodavsky I; Michaeli RI; Bar-Ner M; Fridman R; Horowitz AT; Fuks Z; Biran S
Isr J Med Sci; 1988; 24(9-10):464-70. PubMed ID: 2462549
[TBL] [Abstract][Full Text] [Related]
35. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies.
Khachigian LM; Parish CR
Cardiovasc Drug Rev; 2004; 22(1):1-6. PubMed ID: 14978514
[TBL] [Abstract][Full Text] [Related]
36. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate.
Escobar Galvis ML; Jia J; Zhang X; Jastrebova N; Spillmann D; Gottfridsson E; van Kuppevelt TH; Zcharia E; Vlodavsky I; Lindahl U; Li JP
Nat Chem Biol; 2007 Dec; 3(12):773-8. PubMed ID: 17952066
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
38. Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma.
Zhang Y; Li L; Wang Y; Zhang J; Wei G; Sun Y; Shen F
Biochem Biophys Res Commun; 2007 Jun; 358(1):124-9. PubMed ID: 17467664
[TBL] [Abstract][Full Text] [Related]
39. Heparanase: one molecule with multiple functions in cancer progression.
Vlodavsky I; Elkin M; Abboud-Jarrous G; Levi-Adam F; Fuks L; Shafat I; Ilan N
Connect Tissue Res; 2008; 49(3):207-10. PubMed ID: 18661344
[TBL] [Abstract][Full Text] [Related]
40. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
Ferro V; Liu L; Johnstone KD; Wimmer N; Karoli T; Handley P; Rowley J; Dredge K; Li CP; Hammond E; Davis K; Sarimaa L; Harenberg J; Bytheway I
J Med Chem; 2012 Apr; 55(8):3804-13. PubMed ID: 22458531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
